What TV doesn't, print can't; we deliver.
What TV doesn't, print can't; we deliver.
NEW DELHI: Bharat Biotech’s Covaxin has proven to be ‘safe, well-tolerated, and highly immunogenic’ in children in Phase II/III studies, the results of which are published in the prestigious Lancet journal. The study said that the data from over 50 million doses given to children in India reveals that side effects are minimal. The trials […]
